|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Petrillo A, Pompella L, Tirino G,
Pappalardo A, Laterza MM, Caterino M, Orditura M, Ciardiello F,
Lieto E, Galizia G, et al: Perioperative treatment in resectable
gastric cancer: Current perspectives and future directions. Cancers
(Basel). 11(pii): E3992019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Marin JJ, Al-Abdulla R, Lozano E, Briz O,
Bujanda L, Banales JM and Macias RI: Mechanisms of resistance to
chemotherapy in gastric cancer. Anticancer Agents Med Chem.
16:318–334. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Orditura M, Galizia G, Sforza V,
Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J,
Savastano B, Mabilia A, et al: Treatment of gastric cancer. World J
Gastroenterol. 20:1635–1649. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kaufmann SH and Earnshaw WC: Induction of
apoptosis by cancer chemotherapy. Exp Cell Res. 256:42–49. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li C, Zou J, Zheng G and Chu J: MiR-30a
decreases multidrug resistance (MDR) of gastric cancer cells. Med
Sci Monit. 0:02016.PubMed/NCBI
|
|
9
|
Bao J, Xu Y, Wang Q, Zhang J, Li Z, Li D
and Li J: miR-101 alleviates chemoresistance of gastric cancer
cells by targeting ANXA2. Biomed Pharmacother. 92:1030–1037. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ying G, Wu R, Xia M, Fei X, He QE, Zha C
and Wu F: Identification of eight key miRNAs associated with renal
cell carcinoma: A meta-analysis. Oncol Lett. 16:5847–5855.
2018.PubMed/NCBI
|
|
11
|
Ni F, Zhao H, Cui H, Wu Z, Chen L, Hu Z,
Guo C, Liu Y, Chen Z, Wang X, et al: MicroRNA-362-5p promotes tumor
growth and metastasis by targeting CYLD in hepatocellular
carcinoma. Cancer Lett. 356:809–818. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ni F, Gui Z, Guo Q, Hu Z, Wang X, Chen D
and Wang S: Downregulation of miR-362-5p inhibits proliferation,
migration and invasion of human breast cancer MCF7 cells. Oncol
Lett. 11:1155–1160. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cao R, Wang L, Wang H, Xia L,
Erdjument-Bromage H, Tempst P, Jones RS and Zhang Y: Role of
histone H3 lysine 27 methylation in Polycomb-group silencing.
Science. 298:1039–1043. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Margueron R and Reinberg D: The Polycomb
complex PRC2 and its mark in life. Nature. 469:343–349. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
He LJ, Cai MY, Xu GL, Li JJ, Weng ZJ, Xu
DZ, Luo GY, Zhu SL and Xie D: Prognostic significance of
overexpression of EZH2 and H3k27me3 proteins in gastric cancer.
Asian Pac J Cancer Prev. 13:3173–3178. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xia R, Jin FY, Lu K, Wan L, Xie M, Xu TP,
De W and Wang ZX: SUZ12 promotes gastric cancer cell proliferation
and metastasis by regulating KLF2 and E-cadherin. Tumour Biol.
36:5341–5351. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li H, Cai Q, Wu H, Vathipadiekal V, Dobbin
ZC, Li T, Hua X, Landen CN, Birrer MJ, Sánchez-Beato M and Zhang R:
SUZ12 promotes human epithelial ovarian cancer by suppressing
apoptosis via silencing HRK. Mol Cancer Res. 10:1462–1472. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu C, Shi X, Wang L, Wu Y, Jin F, Bai C
and Song Y: SUZ12 is involved in progression of non-small cell lung
cancer by promoting cell proliferation and metastasis. Tumour Biol.
35:6073–6082. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Su SK, Li CY, Lei PJ, Wang X, Zhao QY, Cai
Y, Wang Z, Li L and Wu M: The EZH1-SUZ12 complex positively
regulates the transcription of NF-kB target genes through
interaction with UXT. J Cell Sci. 129:2343–2353. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhu W, Shan X, Wang T, Shu Y and Liu P:
miR-181b modulates multidrug resistance by targeting BCL2 in human
cancer cell lines. Int J Cancer. 127:2520–2529. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Elmore S: Apoptosis: A review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Petrelli F, Zaniboni A, Ghidini A, Ghidini
M, Turati L, Pizzo C, Ratti M, Libertini M and Tomasello G: Timing
of adjuvant chemotherapy and survival in colorectal, gastric, and
pancreatic cancer. A systematic review and meta-analysis. Cancers
(Basel). 11(pii): E5502019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu W, Chen Q, Wang Q, Sun Y, Wang S, Li A,
Xu S, Røe OD, Wang M, Zhang R, et al: JWA reverses cisplatin
resistance via the CK2-XRCC1 pathway in human gastric cancer cells.
Cell Death Dis. 5:e15512014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ghosh S: Cisplatin: The first metal based
anticancer drug. Bioorg Chem. 88:1029252019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rocha CRR, Silva MM, Quinet A, Cabral-Neto
JB and Menck CFM: DNA repair pathways and cisplatin resistance: An
intimate relationship. Clinics (Sao Paulo). 73 (Suppl 1):e478s2018.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lin Y, Gu Q, Sun Z, Sheng B, Qi C, Liu B,
Fu T, Liu C and Zhang Y: Upregulation of miR-3607 promotes lung
adenocarcinoma proliferation by suppressing APC expression. Biomed
Pharmacother. 95:497–503. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Herr I, Sähr H, Zhao Z, Yin L, Omlor G,
Lehner B and Fellenberg J: MiR-127 and miR-376a act as tumor
suppressors by in vivo targeting of COA1 and PDIA6 in giant cell
tumor of bone. Cancer Lett. 409:49–55. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Feng C, Ma F, Hu C, Ma JA, Wang J, Zhang
Y, Wu F, Hou T, Jiang S, Wang Y and Feng Y: SOX9/miR-130a/CTR1 axis
modulates DDP-resistance of cervical cancer cell. Cell Cycle.
17:448–458. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen J and Li G: MiR-1284 enhances
sensitivity of cervical cancer cells to cisplatin via
downregulating HMGB1. Biomed Pharmacother. 107:997–1003. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yin Y, Liu H, Xu J, Shi D, Zhai L, Liu B,
Wang L, Liu G and Qin J: miR-144-3p regulates the resistance of
lung cancer to cisplatin by targeting Nrf2. Oncol Rep.
40:3479–3488. 2018.PubMed/NCBI
|
|
33
|
Li B, Ding CM, Li YX, Peng JC, Geng N and
Qin WW: Over-regulation of microRNA-133b inhibits cell
proliferation of cisplatin-induced non-small cell lung cancer cells
through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting
EGFR. Oncol Rep. 39:1227–1234. 2018.PubMed/NCBI
|
|
34
|
Gupta RA, Shah N, Wang KC, Kim J, Horlings
HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, et al: Long
non-coding RNA HOTAIR reprograms chromatin state to promote cancer
metastasis. Nature. 464:1071–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
